Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees.  The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Vertex Pharmaceuticals, Inc. adalah perusahaan bioteknologi global yang bergerak dalam bisnis menemukan, mengembangkan, memproduksi, dan memasarkan obat-obatan molekul kecil untuk pasien dengan penyakit serius. Perusahaan ini memiliki markas di Boston, Massachusetts, dan saat ini mempekerjakan 6.100 karyawan tetap. Perusahaan ini telah memiliki tujuh obat yang disetujui: lima yang mengobati penyebab mendasar dari fibrosis kistik (CF), satu yang mengobati penyakit sel sabit berat (SCD) dan thalassemia beta yang bergantung pada transfusi (TDT), serta satu yang mengobati nyeri akut sedang hingga berat. Rencana pengembangan produknya mencakup program-stage klinis dalam CF, SCD, thalassemia beta, nyeri neuropatik akut dan perifer, penyakit ginjal yang dimediasi APOL1, nefropati IgA dan penyakit ginjal autoimun serta sitopenia lainnya, diabetes tipe 1, distrofi miotonik tipe 1, serta penyakit ginjal polikistik autosomal dominan. Obat-obatan yang dipasarkan termasuk TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor dan ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor dan ivacaftor), ORKAMBI (lumacaftor/ivacaftor), dan KALYDECO (ivacaftor).

Vertex Pharmaceuticals

NVIDIA

Apple

Google

Microsoft

Amazon

Broadcom

Meta Platforms

Taiwan Semiconductor

Tesla

Berkshire Hathaway

Walmart

Eli Lilly

JPMorgan

Visa

Oracle

Exxon Mobil

MasterCard

Johnson & Johnson

ASML

SPDR S&P500 ETF

Netflix

Palantir

Bank of America

AbbVie

Costco

Alibaba

Home Depot

Procter & Gamble

Cisco

Chevron

Vanguard Total Stock Market ETF

UnitedHealth Group

Coca-Cola

General Electric

Wells Fargo

Morgan Stanley

Caterpillar

AstraZeneca

Micron Technology

Goldman Sachs

American Express

Toyota

Novartis

Merck

Salesforce

T-Mobile

Philip Morris

Raytheon Technologies

Royal Bank of Canada

McDonald's

Abbott

Applied Materials

Novo Nordisk

Shell

Shopify

Intuitive Surgical

Invesco QQQ Trust

PepsiCo

Citigroup

Lam Research

Intel

Uber

Disney

QUALCOMM

Linde PLC

Blackstone

Intuit

AT&T

Amgen

ServiceNow

Verizon

NextEra Energy

Charles Schwab

Sony

BlackRock

Accenture

Texas Instruments

Booking Holdings

Danaher

Banco Santander

Arista Networks

Boeing

S&P Global

Gilead Sciences

Toronto-Dominion Bank

Capital One

Pfizer

Unilever

Boston Scientific

TotalEnergies

Union Pacific

Adobe

Lowe's

Palo Alto Networks

Vertex Pharmaceuticals Stock

About Vertex Pharmaceuticals

Key Statistics